NCT06329921
Inpatient Monitoring of Unfractionated Heparin
Enrolling by Invitation
NAAges 18+InterventionalHealth servicesVanderbilt University Medical CenterInvestigator-initiated
~700 participants
Updated 2026-07-21 on ClinicalTrials.gov
What's tested:PTT protocolanti-Xa protocol
At a glance
Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Time to therapeutic anticoagulation range
Measured over Randomization to hospital discharge at approximately 5-7 days post-randomization
Conditions
Where it's being run
1 sites across 1 statesTennessee1
Study leadership
- Benjamin Tillman, MD · PRINCIPAL_INVESTIGATOR · Vanderbilt University Medical Center
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Inclusion
Patients at Vanderbilt University Hospital age 18 years and older who are admitted as observation or inpatients for whom intravenous unfractionated heparin (monitored via the PTT nurse-managed protocol) is ordered.
Baseline PTT value is ≥0 and ≤ 36.0 seconds
Baseline heparin level anti-Xa assay value is ≥0 and ≤0.3
Exclusion
Indication for anticoagulation is extracorporeal membrane oxygenation or cerebrovascular ischemic event.
Provider determines patient is not appropriate for the study.
What this trial measures
- Time to therapeutic anticoagulation rangeRandomization to hospital discharge at approximately 5-7 days post-randomization
Time to reach therapeutic anticoagulation range by coagulation assay